IRIS
LORETELLI, CRISTIAN
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.196
EU - Europa 571
AS - Asia 188
AF - Africa 31
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 1.989
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.194
IT - Italia 121
UA - Ucraina 119
SE - Svezia 78
IE - Irlanda 63
CN - Cina 53
DE - Germania 53
SG - Singapore 53
TR - Turchia 53
DK - Danimarca 47
FI - Finlandia 29
GB - Regno Unito 25
KR - Corea 25
CI - Costa d'Avorio 18
FR - Francia 15
BE - Belgio 13
MA - Marocco 13
NL - Olanda 6
CA - Canada 2
EU - Europa 2
IN - India 2
RS - Serbia 2
CO - Colombia 1
KG - Kirghizistan 1
TJ - Tagikistan 1
Totale 1.989
Salva come PNG Salva come JPEG
Città #
Chandler 193
Jacksonville 128
Fairfield 108
Ashburn 64
Boardman 63
Ann Arbor 62
Dublin 62
Wilmington 62
Woodbridge 55
New York 43
Houston 42
Centro 41
Seattle 37
Cambridge 36
Lawrence 26
Princeton 26
San Mateo 26
Des Moines 22
Singapore 21
Abidjan 18
Turin 16
Beijing 15
San Diego 10
Brussels 9
Ancona 7
Cagliari 6
Como 4
Helsinki 4
Kilburn 4
Waanrode 4
Washington 4
Wuxi 4
Izmir 3
London 3
Los Angeles 3
Norwalk 3
Wuhan 3
Arzano 2
Guangzhou 2
New Bedfont 2
Roseto degli Abruzzi 2
San Francisco 2
Acton 1
Amsterdam 1
Belgrade 1
Bishkek 1
Bogotá 1
Burlington 1
Chengdu 1
Chiswick 1
Chizhou 1
Cupra Marittima 1
Dongyang 1
Dushanbe 1
Fayetteville 1
Frankfurt am Main 1
Friesland 1
Hangzhou 1
Hanover 1
Hounslow 1
Jinhua 1
Limerick 1
Newark 1
Ottawa 1
Porto 1
Prescot 1
Pune 1
Qingdao 1
Redwood City 1
San Giuliano 1
Shanghai 1
Spruce Grove 1
Stamford 1
Suzhou 1
Tiantai Chengguanzhen 1
Weitang 1
Woodhall Spa 1
Yiwu 1
Totale 1.283
Salva come PNG Salva come JPEG
Nome #
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 119
'Secrets and lies'--the difficulties of communicating within families with inherited cancer syndromes. 95
A missense germline mutation in exon 7 of the MSH2 gene in a HNPCC family from center-Italy. 92
An intronic mutation in MLH1 associated with familial colon and breast cancer. 89
Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. 88
Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features. 87
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 85
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 83
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. 83
Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression. 82
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 82
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 81
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 79
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 79
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 77
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 76
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 74
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 70
MSH2 splice site mutation and endometrial cancer. 68
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 67
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 66
MSH2 missense mutations and HNPCC syndrome: pathogenicity assessment in a human expression system 65
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 65
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 63
Effectiveness of the CRCAPRO program in identifying patients suspected for HNPCC. 61
Alterazione epigenetica di BRCA1 nei carcinomi mammari 59
Totale 2.035
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.867
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.867
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020142 0 0 0 0 27 2 25 3 28 3 12 42
2020/2021453 28 55 50 7 63 13 38 38 38 55 43 25
2021/2022215 6 60 2 3 4 11 11 12 13 34 16 43
2022/2023499 30 70 28 42 53 67 0 29 120 4 43 13
2023/2024234 34 4 25 25 39 52 6 8 0 3 5 33
2024/2025145 62 47 12 6 18 0 0 0 0 0 0 0
Totale 2.035